157 related articles for article (PubMed ID: 31637762)
1. Personalized treatment selection using data from crossover designs with carry-over effects.
Siriwardhana C; Kulasekera KB; Datta S
Stat Med; 2019 Dec; 38(28):5391-5412. PubMed ID: 31637762
[TBL] [Abstract][Full Text] [Related]
2. A probability based method for selecting the optimal personalized treatment from multiple treatments.
Siriwardhana C; Zhao M; Datta S; Kulasekera KB
Stat Methods Med Res; 2019 Mar; 28(3):749-760. PubMed ID: 29145777
[TBL] [Abstract][Full Text] [Related]
3. Selection of the optimal personalized treatment from multiple treatments with multivariate outcome measures.
Siriwardhana C; Datta S; Kulasekera KB
J Biopharm Stat; 2020 May; 30(3):462-480. PubMed ID: 31691633
[TBL] [Abstract][Full Text] [Related]
4. Quantiles based personalized treatment selection for multivariate outcomes and multiple treatments.
Kulasekera KB; Siriwardhana C
Stat Med; 2022 Jul; 41(15):2695-2710. PubMed ID: 35699385
[TBL] [Abstract][Full Text] [Related]
5. Subgroup analysis with semiparametric models toward precision medicine.
Yuan A; Chen X; Zhou Y; Tan MT
Stat Med; 2018 May; 37(11):1830-1845. PubMed ID: 29575056
[TBL] [Abstract][Full Text] [Related]
6. Mastering variation: variance components and personalised medicine.
Senn S
Stat Med; 2016 Mar; 35(7):966-77. PubMed ID: 26415869
[TBL] [Abstract][Full Text] [Related]
7. Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy.
Laber EB; Zhao YQ; Regh T; Davidian M; Tsiatis A; Stanford JB; Zeng D; Song R; Kosorok MR
Stat Med; 2016 Apr; 35(8):1245-56. PubMed ID: 26506890
[TBL] [Abstract][Full Text] [Related]
8. Bayesian indirect and mixed treatment comparisons across longitudinal time points.
Ding Y; Fu H
Stat Med; 2013 Jul; 32(15):2613-28. PubMed ID: 23229717
[TBL] [Abstract][Full Text] [Related]
9. On optimal treatment regimes selection for mean survival time.
Geng Y; Zhang HH; Lu W
Stat Med; 2015 Mar; 34(7):1169-84. PubMed ID: 25515005
[TBL] [Abstract][Full Text] [Related]
10. Quantifying treatment effects using the personalized chance of longer survival.
Zhao YQ; Redman MW; LeBlanc ML
Stat Med; 2019 Dec; 38(28):5317-5331. PubMed ID: 31502297
[TBL] [Abstract][Full Text] [Related]
11. Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial.
Ghiglietti A; Scarale MG; Miceli R; Ieva F; Mariani L; Gavazzi C; Paganoni AM; Edefonti V
J Biopharm Stat; 2018; 28(6):1203-1215. PubMed ID: 29565749
[TBL] [Abstract][Full Text] [Related]
12. Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.
Shen J; Wang L; Daignault S; Spratt DE; Morgan TM; Taylor JMG
J Biopharm Stat; 2018; 28(2):362-381. PubMed ID: 28934002
[TBL] [Abstract][Full Text] [Related]
13. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
Zhang Z; Chen R; Soon G; Zhang H
Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
[TBL] [Abstract][Full Text] [Related]
14. Enhanced precision in the analysis of randomized trials with ordinal outcomes.
Díaz I; Colantuoni E; Rosenblum M
Biometrics; 2016 Jun; 72(2):422-31. PubMed ID: 26576013
[TBL] [Abstract][Full Text] [Related]
15. Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.
Langford O; Aronson JK; van Valkenhoef G; Stevens RJ
Stat Methods Med Res; 2018 Feb; 27(2):564-578. PubMed ID: 26994216
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Poisson frequency data under a simple crossover trial.
Lui KJ; Chang KC
Stat Methods Med Res; 2016 Feb; 25(1):385-99. PubMed ID: 22899697
[TBL] [Abstract][Full Text] [Related]
17. Multi-Response Based Personalized Treatment Selection with Data from Crossover Designs for Multiple Treatments.
Kulasekera KB; Siriwardhana C
Commun Stat Simul Comput; 2022; 51(2):554-569. PubMed ID: 35299995
[TBL] [Abstract][Full Text] [Related]
18. Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints.
Xu R; Mehrotra DV; Shaw PA
Stat Med; 2018 Oct; 37(23):3280-3292. PubMed ID: 29888552
[TBL] [Abstract][Full Text] [Related]
19. Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials.
Gilbert PB; Yu X; Rotnitzky A
Stat Med; 2014 Mar; 33(6):901-17. PubMed ID: 24123289
[TBL] [Abstract][Full Text] [Related]
20. Selection of the optimal personalized treatment from multiple treatments with right-censored multivariate outcome measures.
Siriwardhana C; Kulasekera KB; Datta S
J Appl Stat; 2024; 51(5):891-912. PubMed ID: 38524800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
